Europe's Biopsy Devices Market reached US$ 636.4 Million in 2023. It is projected to grow at a CAGR of 5.99% from 2024 to 2032. The analyst forecasts it to reach US$ 1,074.0 Million by 2032.
Biopsy devices are essential in European healthcare. They extract tissue samples vital for diagnosing illnesses like cancer and play a pivotal role in ensuring correct analysis and effective treatment plans. The demand for those gadgets continues to surge because of rising cancer rates and a developing emphasis on early detection and customized remedies. Technological improvements like minimally invasive biopsy techniques also propel their adoption throughout Europe. This allows healthcare experts to conduct procedures more precisely and decrease patient discomfort.
The UK also hosts numerous outstanding scientific device producers and research institutions devoted to pioneering revolutionary biopsy technology. These entities are pivotal in driving the increase and advancement of the biopsy device market locally and across Europe. Governmental projects and investment allocations for clinical research further solidify the UK's importance as a critical player in the Europe biopsy device market. This ensures continuous progress and innovation. As part of the NHS Cervical Screening Programme, women aged 25 to 64 are routinely invited for cervical screening. This targets to pick out cervix abnormalities early to prevent the development of cervical cancer if left undetected and untreated.
In September 2023 - Mermaid Medical unveiled its latest soft tissue biopsy solutions, featuring the M∙Biopsy® Semi-Automatic and Fully Automatic Biopsy Needles.
In August 2022 - Mammotome introduced the inaugural Vacuum-Assisted Breast Biopsy System tailored for Lesion Excision.
In August 2022 - Throughout Europe, Predicine introduced its CE-marked PredicineCARE for genomic profiling in blood and urine. The liquid biopsy assay, targeting 152 genes, is tailored for cancer patients' diagnosis.
In May 2022 - Guardant Health, Inc. revealed the availability of Europe's initial blood-based cancer testing services at the VHIO liquid biopsy testing facility in Barcelona. These services are founded on Guardant Health's cutting-edge digital sequencing platform
2. Biopsy Forceps
3. Localization Wire
4. Others Products
2. Stereotactic Guided
3. Ultrasound Guided
4. MRI Guided
5. Others
2. Diagnostics Laboratories
3. Other
2. France
3. Germany
4. Italy
5. Spain
6. Russia
7. Rest of Europe
2. Thermo Fisher Scientific Inc.
3. Bio-Rad Laboratories
4. Exact Sciences (Genomic Health)
5. Biocept
6. Roche Diagnostics
7. Myriad Genetics Inc.
8. Qiagen
9. NeoGenomics Laboratories
10. Quest Diagnostics Inc.
Biopsy devices are essential in European healthcare. They extract tissue samples vital for diagnosing illnesses like cancer and play a pivotal role in ensuring correct analysis and effective treatment plans. The demand for those gadgets continues to surge because of rising cancer rates and a developing emphasis on early detection and customized remedies. Technological improvements like minimally invasive biopsy techniques also propel their adoption throughout Europe. This allows healthcare experts to conduct procedures more precisely and decrease patient discomfort.
Europe Biopsy Devices Growth Factors
Persistent Health Conditions
Chronic ailments in Europe, including cancer, are ordinary, with over one-third (36.1%) of EU residents reporting long-standing health troubles in 2022 (Eurostat). Early and correct analysis is essential for remedy fulfillment, central to the multiplied demand for biopsy methods to acquire tissue samples. Biopsy devices are vital equipment facilitating sample extraction for evaluation. As healthcare systems address rising diagnostic wishes, demand for biopsy devices grows. This emphasizes their essential position in diagnosing chronic illnesses, particularly cancer, throughout Europe.The Population of Europe is Experiencing Aging
As the population of Europe ages, the prevalence of illnesses requiring biopsies will increase. This is particularly true amongst older adults, who are more vulnerable to fitness issues. The European Commission states that as of 2023, the EU population stood at 448.8 million, with over one-fifth (21.3%) aged sixty-five years and above. The median age of the EU's populace reached 44.5 years by the same date. This demographic transition propels the boom of the Europe biopsy devices market as the demand for those tools escalates to ensure particular analysis and treatment of age-associated illnesses.Transition towards Personalized Treatments
The shift to personalized remedies emphasizes the want for precise diagnoses through tissue biopsies. This fuels the demand for advanced biopsy devices in Europe. Accurate tissue sampling is vital for tailor-made treatments based on patient genetics and clinical needs. For instance, Sorek Medical Systems Ltd. evolved biopsy devices that robotically split tissue samples for chemical fixation and freezing preservation. EU-funded testing targets to validate these devices for medical applications, probably reaping the rewards for cancer prognosis and pharmaceutical development for personalized medicinal drugs. Innovative biopsy technology refines diagnostics, improving patient outcomes and advancing personalized medicinal drug initiatives continent-wide.Government Initiatives are Vigorously advancing Cancer Screening Programs
European governments actively promote cancer screening programs and support studies in clinical technologies. Europe's Beating Cancer Plan prioritizes prevention, early detection, diagnosis, and treatment, enhancing cancer sufferers' and survivors' quality of life. The EU4Health project, a part of this plan, launches SOLACE to enlarge lung cancer screening throughout Europe. This initiative aims to ensure screening accessibility for all social and economic companies. Governments foster a positive environment for growing the Europe biopsy devices market specializing in early cancer detection and treatment. This strategic technique stimulates innovation and funding, driving increased demand for advanced diagnostic tools to combat cancer successfully.Needle-based biopsy devices might rank as a top product in the Europe Biopsy Devices Market
Needle-based biopsy devices are among the leading products in the Europe biopsy devices market. This is because they effectively obtain tissue samples for accurate analysis. These gadgets offer minimally invasive approaches, decreasing patient discomfort and recuperation time. With the rising demand for precise and efficient biopsy techniques, healthcare professionals and European patients prefer needle-based biopsy devices.United Kingdom Biopsy Devices Market
The United Kingdom commands a notable part of the Europe biopsy devices market. Research posted in the esteemed cancer journal Annals of Oncology states that in 2023, about 172,314 individuals in the UK are projected to succumb to cancer, contributing to a total of 261,990 cancer-related deaths within the EU (EU-27). The UK's healthcare system is recognized for its robustness, particularly in prioritizing the early detection and treatment of illnesses like cancer. This cognizance underscores the demand for biopsy devices as critical equipment for specific diagnosis in the UK healthcare sector.The UK also hosts numerous outstanding scientific device producers and research institutions devoted to pioneering revolutionary biopsy technology. These entities are pivotal in driving the increase and advancement of the biopsy device market locally and across Europe. Governmental projects and investment allocations for clinical research further solidify the UK's importance as a critical player in the Europe biopsy device market. This ensures continuous progress and innovation. As part of the NHS Cervical Screening Programme, women aged 25 to 64 are routinely invited for cervical screening. This targets to pick out cervix abnormalities early to prevent the development of cervical cancer if left undetected and untreated.
Europe Biopsy Devices Company News
Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Exact Sciences (Genomic Health), Biocept, Roche Diagnostics, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories, and Quest Diagnostics Inc. are the essential companies in the Europe biopsy devices market.In September 2023 - Mermaid Medical unveiled its latest soft tissue biopsy solutions, featuring the M∙Biopsy® Semi-Automatic and Fully Automatic Biopsy Needles.
In August 2022 - Mammotome introduced the inaugural Vacuum-Assisted Breast Biopsy System tailored for Lesion Excision.
In August 2022 - Throughout Europe, Predicine introduced its CE-marked PredicineCARE for genomic profiling in blood and urine. The liquid biopsy assay, targeting 152 genes, is tailored for cancer patients' diagnosis.
In May 2022 - Guardant Health, Inc. revealed the availability of Europe's initial blood-based cancer testing services at the VHIO liquid biopsy testing facility in Barcelona. These services are founded on Guardant Health's cutting-edge digital sequencing platform
Product - Market breakup in 4 viewpoints:
1. Needle Based Biopsy Devices2. Biopsy Forceps
3. Localization Wire
4. Others Products
Imaging Technology - Market breakup in 5 viewpoints:
1. CT scan2. Stereotactic Guided
3. Ultrasound Guided
4. MRI Guided
5. Others
End-User - Market breakup in 3 viewpoints:
1. Hospital and Clinics2. Diagnostics Laboratories
3. Other
Country - Market breakup of 5 Countries:
1. United Kingdom2. France
3. Germany
4. Italy
5. Spain
6. Russia
7. Rest of Europe
All the key players have been covered from 3 viewpoints:
- Overview
- Recent Development
- Revenue Analysis
Company Analysis:
1. Becton, Dickinson and Company2. Thermo Fisher Scientific Inc.
3. Bio-Rad Laboratories
4. Exact Sciences (Genomic Health)
5. Biocept
6. Roche Diagnostics
7. Myriad Genetics Inc.
8. Qiagen
9. NeoGenomics Laboratories
10. Quest Diagnostics Inc.
Table of Contents
1. Introduction2. Research Methodology3. Executive Summary5. Europe Biopsy Device Market
4. Market Dynamics
6. Market Share
7. Product
8. Imaging Technology
9. Country
10. End User
11. Porter's Five Forces Analysis
12. SWOT Analysis
13. Key Players Analysis
List of Figures
List of Tables
Companies Mentioned
- Becton, Dickinson and Company
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories
- Exact Sciences (Genomic Health)
- Biocept
- Roche Diagnostics
- Myriad Genetics Inc.
- Qiagen
- NeoGenomics Laboratories
- Quest Diagnostics Inc.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 636.4 Million |
| Forecasted Market Value ( USD | $ 1074 Million |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 10 |
